Login to Your Account

HGS' Albugon For Diabetes Nets $183M Deal With GSK

By Randall Osborne

Wednesday, October 27, 2004
Human Genome Sciences Inc.'s Albugon for diabetes drew a development and commercialization deal worth up to $183 million with GlaxoSmithKline plc, which gets worldwide rights to albumin-glucagon-like peptide-1. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription